Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well genetic testing works in guiding treatment for patients
with solid tumors that have spread to the brain. Several genes have been found to be altered
or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these
genes such as abemaciclib, paxalisib, and entrectinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor
treatment for each mutation.